NCT00842140View on ClinicalTrials.gov

Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women

NACompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

oral contraceptive

oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months

DRUG

Oral contraceptive plus spironolactone

The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.

DRUG

Oral contraceptive plus metformin

Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin

Trial Locations (1)

14049-900

University of Sao Paulo, Ribeirão Preto

All Listed Sponsors
lead

University of Sao Paulo

OTHER

NCT00842140 - Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women | Biotech Hunter | Biotech Hunter